window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 10, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

exatecan linker payload

  • Biologics & Biosimilars,Biotech,Oncology,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    Synaffix and Qurient partner on dual-payload ADC for solid tumours

    Lonza’s Synaffix has signed a licensing agreement with Qurient Therapeutics [...]

    September 25, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Genmab appoints Margarida Duarte as general manager for Europe and emerging markets
    Categories: Healthcare leadership, Mergers & Acquisitions, Movers & Shakers, Pharmaceuticals and therapeutics
  • Opella appoints former Reckitt executive Gonzalo Balcazar to lead Europe and Latin America
    Categories: Healthcare leadership, Market Access & Commercialization, Movers & Shakers, Pharmaceuticals and therapeutics, Startups and innovations
  • Orano Med appoints Frederic Desdouits as CEO to advance targeted alpha therapy pipeline
    Categories: Biotech, Healthcare leadership, Movers & Shakers, Oncology, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top